Genocea Biosciences (GNCAQ) Competitors

$0.0001 0.00 (0.00%)

As of 05/22/2026 10:59 AM Eastern

GNCAQ vs. SCNI, SYRS, MEHA, ITRM, and SXTC

Should you buy Genocea Biosciences stock or one of its competitors? MarketBeat compares Genocea Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genocea Biosciences include Scinai Immunotherapeutics (SCNI), Syros Pharmaceuticals (SYRS), Functional Brands (MEHA), Iterum Therapeutics (ITRM), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry.

How does Genocea Biosciences compare to Scinai Immunotherapeutics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Scinai Immunotherapeutics had 2 more articles in the media than Genocea Biosciences. MarketBeat recorded 2 mentions for Scinai Immunotherapeutics and 0 mentions for Genocea Biosciences. Scinai Immunotherapeutics' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Genocea Biosciences	Neutral

Scinai Immunotherapeutics has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market.

Genocea Biosciences has lower revenue, but higher earnings than Scinai Immunotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	1.25	-$8.31M	-$9.57	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genocea Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Scinai Immunotherapeutics beats Genocea Biosciences on 5 of the 7 factors compared between the two stocks.

How does Genocea Biosciences compare to Syros Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Genocea Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Genocea Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

Genocea Biosciences has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Syros Pharmaceuticals	Neutral

Summary

Syros Pharmaceuticals beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

How does Genocea Biosciences compare to Functional Brands?

Genocea Biosciences (NASDAQ:GNCAQ) and Functional Brands (NASDAQ:MEHA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

In the previous week, Functional Brands had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Functional Brands and 0 mentions for Genocea Biosciences. Functional Brands' average media sentiment score of 0.21 beat Genocea Biosciences' score of 0.00 indicating that Functional Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Functional Brands	Neutral

Functional Brands has higher revenue and earnings than Genocea Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Functional Brands	$6.61M	0.35	$760K	-$0.32	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Functional Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Functional Brands	N/A	N/A	N/A

Summary

Functional Brands beats Genocea Biosciences on 4 of the 5 factors compared between the two stocks.

How does Genocea Biosciences compare to Iterum Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Genocea Biosciences has lower revenue, but higher earnings than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

9.2% of Iterum Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Genocea Biosciences	N/A	N/A	N/A

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Genocea Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Genocea Biosciences	Neutral

Summary

Iterum Therapeutics beats Genocea Biosciences on 5 of the 7 factors compared between the two stocks.

How does Genocea Biosciences compare to China SXT Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Genocea Biosciences has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
China SXT Pharmaceuticals	Neutral

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genocea Biosciences has higher earnings, but lower revenue than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
China SXT Pharmaceuticals	$1.74M	0.89	-$3.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
China SXT Pharmaceuticals	N/A	N/A	N/A

Summary

China SXT Pharmaceuticals beats Genocea Biosciences on 4 of the 5 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNCAQ vs. The Competition

Export

Metric	Genocea Biosciences	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5K	$309.61M	$6.46B	$12.34B
Dividend Yield	N/A	N/A	2.76%	5.28%
P/E Ratio	0.00	N/A	21.22	25.66
Price / Sales	N/A	189.70	562.28	86.31
Price / Cash	N/A	22.44	43.49	56.67
Price / Book	N/A	4.77	10.31	7.14
Net Income	N/A	-$132.96M	$3.57B	$335.98M
7 Day Performance	N/A	2.45%	6.43%	4.15%
1 Month Performance	N/A	31.23%	3.57%	2.54%
1 Year Performance	N/A	77.59%	34.07%	35.06%

Genocea Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNCAQ Genocea Biosciences	N/A	$0.00 flat	N/A	N/A	$5K	N/A	N/A	70
SCNI Scinai Immunotherapeutics	0.2695 of 5 stars	$0.51 -9.3%	N/A	-83.2%	$1.80M	$1.31M	N/A	20
SYRS Syros Pharmaceuticals	N/A	$0.00 -50.0%	N/A	-98.7%	$1.65M	$386K	N/A	120
MEHA Functional Brands	0.5921 of 5 stars	$0.07 -5.8%	N/A	N/A	$1.62M	$6.61M	N/A	33	Gap Down
ITRM Iterum Therapeutics	0.0885 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genocea Biosciences (GNCAQ) Competitors

GNCAQ vs. SCNI, SYRS, MEHA, ITRM, and SXTC

How does Genocea Biosciences compare to Scinai Immunotherapeutics?

Summary

How does Genocea Biosciences compare to Syros Pharmaceuticals?

Summary

How does Genocea Biosciences compare to Functional Brands?

Summary

How does Genocea Biosciences compare to Iterum Therapeutics?

Summary

How does Genocea Biosciences compare to China SXT Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNCAQ vs. The Competition

Genocea Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genocea Biosciences (GNCAQ) Competitors

GNCAQ vs. SCNI, SYRS, MEHA, ITRM, and SXTC

How does Genocea Biosciences compare to Scinai Immunotherapeutics?

Does the media prefer SCNI or GNCAQ?

Which has more risk & volatility, SCNI or GNCAQ?

Which has better valuation and earnings, SCNI or GNCAQ?

Do analysts recommend SCNI or GNCAQ?

Is SCNI or GNCAQ more profitable?

Do insiders and institutionals have more ownership in SCNI or GNCAQ?

Summary

How does Genocea Biosciences compare to Syros Pharmaceuticals?

Is GNCAQ or SYRS more profitable?

Do institutionals & insiders have more ownership in GNCAQ or SYRS?

Which has higher valuation & earnings, GNCAQ or SYRS?

Which has more risk & volatility, GNCAQ or SYRS?

Does the media refer more to GNCAQ or SYRS?

Summary

How does Genocea Biosciences compare to Functional Brands?

Does the media refer more to GNCAQ or MEHA?

Which has better earnings and valuation, GNCAQ or MEHA?

Do analysts recommend GNCAQ or MEHA?

Is GNCAQ or MEHA more profitable?

Summary

How does Genocea Biosciences compare to Iterum Therapeutics?

Which has stronger earnings & valuation, ITRM or GNCAQ?

Do institutionals and insiders hold more shares of ITRM or GNCAQ?

Is ITRM or GNCAQ more profitable?

Which has more volatility and risk, ITRM or GNCAQ?

Do analysts recommend ITRM or GNCAQ?

Does the media prefer ITRM or GNCAQ?

Summary

How does Genocea Biosciences compare to China SXT Pharmaceuticals?

Which has more volatility & risk, GNCAQ or SXTC?

Does the media refer more to GNCAQ or SXTC?

Do institutionals & insiders believe in GNCAQ or SXTC?

Do analysts recommend GNCAQ or SXTC?

Which has preferable valuation & earnings, GNCAQ or SXTC?

Is GNCAQ or SXTC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNCAQ vs. The Competition

Genocea Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools